Amid reports that Russian-Israeli businessman Arcadi Gaydamak fled Israel Friday morning, apparently for Russia, TheMarker has learned that he recently put his properties in Caesarea up for sale at a combined asking price of $30 million. Last week representatives of Gaydamak spoke with real estate agents in the coastal town about finding potential buyers.
The mogul has already listed a villa he owns in Herzliya, for which he is asking $4 million-$4.5 million, and is trying to sell off his main real estate holding in Israel - Jerusalem's Bikur Holim hospital that he purchased for $32 million about two years ago. Talks with the Levinger family, which operates the Einayim chain of eye clinics, fell through but negotiations for the hospital's purchase are now underway with a medical institution. Senior hospital officials are refusing to reveal the identity of the potential buyers or the numbers being bandied about. There is a lien on the property.
Gaydamak's main residential property in Israel is his home in Caesarea, on Hadar Street in Cluster 6. Gaydamak bought the house in 2001 from cardiac surgeon Prof. Danny Gur at the then-record price of $7.5 million. The 1,000-square-meter home sits on a four-dunam (about one acre) lot. Gaydamak later purchased two adjacent lots, one of 1.25 dunams with a 350-sq.-meter home on it, the second of two dunams (about half an acre).
Even at the height of the real estate market the combined price of the three properties would never have fetched the $30 million he is asking for today. Local real estate people estimate the total value of the package at no more than $14 million, even when the fact that the three properties are adjacent is figured in.
About two weeks ago it was reported that Gaydamak was negotiating over the sale of his Herzliya Pituah house for $4.5 million, after a year of attempting to sell it with a price tag of about $5 million. This is a 675-square-meter home with three stories plus a basement, on a one-dunam lot on Havatzelet Hasharon Street, close to De Shalit Square.